Clinical Trials
Trefoil Therapeutics is dedicated to advancing novel engineered FGF1 (eFGF1) products to treat corneal diseases and disorders. We have ongoing laboratory research and are actively conducting clinical research that will allow us to evaluate the safety and efficacy of our lead compound, TTHX1114. You can learn more can learn more about our clinical trials below.
If you have questions about our clinical trials, please contact us:
Trefoil Clinical Trials
STORM Clinical Trial
Status: ENROLLMENT COMPLETED
Trefoil’s STORM clinical trial has completed enrollment. For additional information, please contact us.
INTREPID Clinical Trial
Status: COMPLETED
Trefoil completed this Phase 1/2 Study of TTHX1114(NM141). For additional information, please contact us.
Have Other Questions?
